Stifel resumed coverage of MEDNAX with a rating of Hold and set a new price target of $30.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/26/2024 | $8.00 → $14.00 | Hold → Buy | Jefferies |
| 6/7/2024 | $8.00 | Sell → Hold | Deutsche Bank |
| 2/23/2022 | $32.00 → $31.00 | Outperform | Credit Suisse |
| 12/22/2021 | $33.00 → $32.00 | Outperform | Credit Suisse |
| 11/4/2021 | $29.00 → $27.00 | Market Perform | SVB Leerink |
| 9/27/2021 | $29.00 | Market Perform | SVB Leerink |
| 8/9/2021 | $30.00 → $32.00 | Neutral | Mizuho |
| 6/23/2021 | $30.00 | Hold | Stifel |
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
3 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.23 per share for the three months ended September 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2024 third quarter, Pediatrix reported the following results: Net revenue of $511 million; Net income of $19 million; and Adjusted EBITDA of $60 million. "Our third quarter operating results modestly exceeded our expectations, driven primarily by strength in same-unit revenue," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "During the quarter, we successfully completed our previously announced transition to a
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Friday, November 1, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2024. A detailed press release will be issued the morning of November 1, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and ch
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported a loss of $1.84 per share for the three months ended June 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.34. For the 2024 second quarter, Pediatrix reported the following results: Net revenue of $504 million; Net loss of $153 million; and Adjusted EBITDA of $58 million. "Our second quarter operating results exceeded our expectations and reflected stable patient volumes, improved payor mix, and operating efficiencies," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our previously discussed portfolio management plans are well un
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today announced that its board of directors has appointed Sylvia Young, a recognized leader in healthcare and long-term healthcare executive, as an independent director, effective May 12, 2023. Ms. Young, a veteran of hospital administration since 1985, most recently served as President and CEO of the HCA Continental Division, a multi-state regional healthcare system that is part of Hospital Corporation of America (HCA). Prior to her appointment to the Denver-based Division headquarters, Ms. Young served as President of HCA's Sunrise Health System, inclu
PALM BEACH, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- BurgerFi International, Inc. (NASDAQ:BFI, BFIIW))) ("BurgerFi" or the "Company"), one of the nation's fastest-growing premium fast-casual concepts, has appointed Vivian Lopez-Blanco to its board of directors, effective July 14, 2021. Lopez-Blanco's appointment follows the sudden passing of board member Steven Berrard announced on June 10, 2021. Lopez-Blanco has also been named as the chair of the audit committee and will be serving on the compensation committee and nominating governance committee. Lopez-Blanco is an experienced board member and seasoned finance executive with expertise in organizational transformations and driving prof
SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
Truist Securities analyst David Macdonald maintains Pediatrix Medical Group (NYSE:MD) with a Hold and lowers the price target from $10 to $8.
Deutsche Bank analyst Pito Chickering upgrades Pediatrix Medical Group (NYSE:MD) from Sell to Hold and maintains the price target from $8 to $8.
In the preceding three months, 4 analysts have released ratings for Pediatrix Medical Group (NYSE:MD), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 3 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $9.5, a high estimate of $10.00, and a low estimate of $9.00. This current average has
10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.23 per share for the three months ended September 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2024 third quarter, Pediatrix reported the following results: Net revenue of $511 million; Net income of $19 million; and Adjusted EBITDA of $60 million. "Our third quarter operating results modestly exceeded our expectations, driven primarily by strength in same-unit revenue," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "During the quarter, we successfully completed our previously announced transition to a
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Friday, November 1, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2024. A detailed press release will be issued the morning of November 1, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and ch
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported a loss of $1.84 per share for the three months ended June 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.34. For the 2024 second quarter, Pediatrix reported the following results: Net revenue of $504 million; Net loss of $153 million; and Adjusted EBITDA of $58 million. "Our second quarter operating results exceeded our expectations and reflected stable patient volumes, improved payor mix, and operating efficiencies," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our previously discussed portfolio management plans are well un
Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously
Deutsche Bank upgraded Pediatrix Medical Group from Sell to Hold and set a new price target of $8.00
Credit Suisse reiterated coverage of Mednax with a rating of Outperform and set a new price target of $31.00 from $32.00 previously